| Similar Articles |
|---|
 |
Chemistry World
October 8, 2014
Rebecca Trager |
US tax changes ripple into merger deals The tightened tax rules are pressuring pharmaceutical and medical devices companies to reconsider deals announced recently, according to financial analysts.   |
Chemistry World
July 25, 2014
Anthony King |
Pharma firms rush to escape US tax shackles US drug company AbbVie has persuaded Hampshire-based, Irish-headquartered Shire to enter a mega-merger. The enlarged firm will cut its US tax bill. |
Chemistry World
August 10, 2015
Rebecca Trager |
Shire makes hostile bid for Baxalta Baxalta rejected Shire's initial private offer in July 2015, and the same outcome appears likely this time around. |
Chemistry World
June 23, 2014
Phillip Broadwith |
Shire fends off AbbVie takeover bid Shire is the latest pharmaceutical company to be targeted for a multi-billion dollar takeover deal from a firm looking to transfer its tax residence outside the US. |
The Motley Fool
July 5, 2005
Bill Mann |
This Merger Deserves Revisiting Transkaryotic agreed to $37 per share from Shire Pharmaceuticals -- but that was before the good news rolled in. These shares are worth 30% more today. The market knows it. |
Chemistry World
March 10, 2015
Anmdrew Turley |
AbbVie to buy Pharmacyclics for pipeline boost AbbVie has agreed to buy US biotech Pharmacyclics for $21 billion in a bid to re-stock its pipeline. |
The Motley Fool
October 30, 2006
Brian Lawler |
Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note. |
Chemistry World
November 11, 2013
Phillip Broadwith |
Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke. |
The Motley Fool
October 9, 2007
Brian Lawler |
Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises. |
Chemistry World
January 26, 2015
Phillip Broadwith |
Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion. |
The Motley Fool
February 26, 2007
Brian Lawler |
Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition. |
Chemistry World
September 25, 2013
Phillip Broadwith |
Nanobody inflammation drug attracts Abbvie Belgian biotech firm Ablynx has agreed a global licensing deal with Abbvie for its nanobody drug candidate ALX-0061. |
